Originally published as JCO Early Release 10.1200/JCO.2004.06.144 on March 22 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morris, C. Articles by Gahrton, G. Search for Related Content PubMed PubMed Citation Articles by Morris, C. Articles by Gahrton, G.

Benefit and Timing of Second Transplantations in Multiple Myeloma: Clinical Findings and Methodological Limitations in a European Group for Blood and Marrow Transplantation Registry Study

From the Haematology Department, Belfast City Hospital, Belfast, Northern Ireland; University Medical Centre, Leiden, the Netherlands; Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden; Division of Haematology and Oncology, University of Leipzig, Leipzig, Germany; on behalf of the Chronic Leukaemia Working Party Myeloma Subcommittee of the European Blood and Marrow Transplantation Group

Address reprint requests to T.C.M. Morris, MD, Department of Haematology (C floor), Belfast City Hospital, Lisburn Rd, Belfast, BT9 7AB Northern Ireland; e-mail: curly.morris{at}bll.n-i.nhs.uk

PURPOSE: To use European Group for Blood and Marrow Transplantation registry data to assess the benefit and optimal timing of a double-autologous transplantation strategy for patients with myeloma.

PATIENTS AND METHODS: 7,452 transplantation patients described as being either in a multiple graft program ("planned") or not, were analyzed on an intention-to-treat basis. Subsequent multivariate analyses concentrated on the real occurrence of second transplantation, survival, relapse, and transplant-related mortality.

RESULTS: Although the transplantation rate in the planned group failed to reach 60%, the median survival from transplantation is 60 months for the planned, compared with 51 months for the remainder group. While the hazard ratio of the planned group is 0.89 (95% CI, 0.79 to 1.00; P =.05) before approximately 70 months, this "effect" is reversed after 70 months, with the hazard ratio estimated as 3.01 (95% CI, 1.07 to 8.46; P = .04). A time-dependent multivariate Cox analysis shows that, taking patients without a second transplantation as a reference group, those receiving a second transplantation in first remission (ie, before relapse) show an increased probability of transplant-related mortality, especially if the transplantation is performed more than 12 months after the first, and the reduction of the risk of relapse is less than when the transplantation is performed earlier. Performing a second transplantation after relapse does not seem to prolong survival, though a second transplantation before relapse is associated with a higher probability of mortality.

CONCLUSION: To improve survival of tandem autologous transplantation in multiple myeloma, the second transplantation should preferably be performed before relapse and within 6 to 12 months of the first transplantation.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				A. Abdelkefi, S. Ladeb, L. Torjman, T. B. Othman, A. Lakhal, N. B. Romdhane, H. E. Omri, M. Elloumi, H. Belaaj, R. Jeddi, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial Blood, February 15, 2008; 111(4): 1805 - 1810. [Abstract] [Full Text] [PDF]

				K.-S. Eom, C.-K. Min, S. Lee, Y.-J. Kim, S.-Y. Kim, H.-J. Kim, J.-W. Lee, W.-S. Min, and C.-C. Kim Efficacy of Up-Front Treatment with a Double Stem Cell Transplantation in Multiple Myeloma Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 432 - 438. [Abstract] [Full Text] [PDF]